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Editorial
The appropriate antiparasitic treatment: Coping with emerging
threats from old adversaries
Conventional strategies for equine helminth control involve prophylactic
anthelmintic treatments administered at scheduled intervals or applied at
tactical times during the year [1]. In recent years, however, increasing
emphasis has been placed on the use of diagnostic surveillance to
generate information on the types of parasites present and the level of
helminth egg excretion, and to evaluate treatment efficacy [2]. As a result
of such recommendations, efforts have been made to develop novel
species-specific diagnostic tools that detect the presence of particular
species of interest. This issue of the Equine Veterinary Journal hosts two
articles that focus on the diagnosis of 2 important equine pathogens;
Parascaris spp. [3] and Strongylus vulgaris [4]. For both parasites, an
obvious question to ask is: “What is the treatment of choice when a given
parasitic infection is detected?” While there is some scientific information
available to help answer this question, there is a real paucity of
underpinning evidence, and often treatment decisions are based on the
practitioner’s experience. Here we provide our considerations for treating
a horse with: 1) a sizeable Parascaris spp. burden diagnosed by
ultrasonography, or 2) S. vulgaris infection diagnosed with coproculture or
serology.
Parascaris spp.
As outlined in the research article presented in this issue [3], recent
anthelmintic treatment is a risk factor for verminous impactions of the
small intestine and there is a need to define the optimal clinical approach
for a foal with ultrasonographic evidence of a large Parascaris spp. burden.
There are no published studies that have directly evaluated the immediate
or long-term consequences of deworming foals that harbour large ascarid
burdens, so this challenge is not easily answered. However, some
information can be derived from the literature. For example, 2 publications
encompassing a total of 34 clinical cases determined that the majority of
ascarid impactions were associated with the administration of
anthelmintics with a ‘paralytic’ mode of action, i.e. pyrantel pamoate or
ivermectin [5,6]. In contrast, a benzimidazole anthelmintic was
administered in only one case. While this could merely reflect the
frequency of the anthelmintic classes used, one interpretation is that
benzimidazole therapy might be associated with a lower risk of impaction
[7]. There is some logic to this hypothesis because benzimidazoles do not
paralyse worms; rather they disrupt cellular metabolism. Thus, if
benzimidazoles cause worms to die more slowly, a more gradual removal
of worms ensues and the risk of impaction is reduced. Although this seems
like a reasonable explanation, more research is needed to test this
hypothesis. Another important factor to consider is the expected efficacy
of the available anthelmintics. Ivermectin-resistant Parascaris populations
are commonly reported in managed horses worldwide [8], whereas
resistance to pyrantel or benzimidazoles has only been identified in a few
studies [8]. However, the prevalence of resistance in Parascaris spp. has
not been well studied; thus there is a need to perform region-wide studies
for all 3 major drug classes to determine the prevalences of resistance in
this parasite.
Taken together, the relatively limited available evidence suggests that a
benzimidazole drug may be the drug of choice for foals when there is
evidence, or a suspicion, of a large ascarid burden. The literature does
not offer recommendations regarding dosage or, in relevant locales,
choice of benzimidazole. Also, there is no published evidence to suggest
that clinicians should use a higher or lower dosage of benzimidazole
than the labelled recommendation. Some veterinarians elect to treat first
with a half dose of a given anthelmintic and then follow up with a full
dose about one week later. However, the potential consequences of
such an approach have not been investigated. A 5-day regimen of
fenbendazole given at a 10 mg/kg bwt has been shown to treat
migrating ascarid larvae effectively in the lungs [9], and may offer some
clinical benefits to heavily exposed foals. Some veterinarians recommend
administering mineral oil via nasogastric tube to facilitate the passage of
dead or dying worms. However, there is no scientific evidence for the
clinical benefits of this procedure and the passing of a nasogastric tube
can be stressful to a foal. It is also unknown whether a mineral
oil-coated alimentary tract absorbs and metabolises anthelmintics as
expected or whether mineral oil might interfere directly with the
anthelmintic. Certainly, it is recommended that foals presenting with
evidence of a large ascarid burden be kept under observation for the
first 24–48 h following treatment.
Strongylus vulgaris
Historically, S. vulgaris was the most important parasitic helminth of
horses, and the report in this issue of EVJ documents the continued
pathogenic potential of this parasite in managed horses [4]. Faecal egg
counts do not reveal the presence of this parasite specifically, as it
produces an egg similar to those of other equine strongyle species.
Definitive testing therefore requires coprocultures and examination of third
stage larvae, although polymerase chain reaction and a serum enzyme-
linked immunosorbent assay have been developed for research purposes
[10,11]. If increased testing for S. vulgaris is to be recommended, it is
relevant to ask: what would be the most appropriate therapeutic option
when a horse tests positive? All available evidence suggests that
S. vulgaris has yet to develop resistance to any of the currently available
anthelmintic formulations. In fact, this is a main explanation as to why this
parasite has become ‘rare’ in most managed equine populations. This
susceptibility pattern indicates that any registered anthelmintic could be
used to treat the parasite, but each has relevant properties to consider.
Pyrantel salts, for example, only have efficacy against intestinal stages, and,
hence, do not kill migrating larvae. Given the lengthy migratory phase of
several months for S. vulgaris, it would be preferable to use an
anthelmintic with larvicidal properties, i.e. a macrocyclic lactone. Efficacy
levels against S. vulgaris larvae in the cranial mesenteric artery have been
assumed to be similar for ivermectin and moxidectin, although one study
reported higher efficacy for moxidectin [12]. A recent investigation
suggested that early fifth stage larvae, present in the arterial lumen,
responded poorly to ivermectin treatment, although good efficacy against
fourth stage larvae was observed [13]. Fenbendazole has also been
reported to have good activity against migrating larvae of S. vulgaris at
10 mg/kg bwt when given over at least 3 days [14], and probably remains
a valid larvicidal treatment option for this parasite.
A question often asked by veterinarians is whether adverse reactions
might occur when treating a horse harbouring a large burden of arterial
larvae. One, often-expressed concern is whether treatment can lead to, or
exaggerate production of, thromboemboli, due to decay of dead worms in
the arterial lumen. There are no published studies to support this
hypothesis. On the contrary, it has been described that arterial larvae
remain viable for at least 14 days following ivermectin treatment, and that
they are eventually killed/eliminated by a cellular host immune response
occurring over a period of several weeks [15]. Some practitioners have
elected to supplement anthelmintic treatment with corticosteroids to
dampen a presumed local inflammatory response following treatment;
however, there is no scientific basis to support this procedure. In fact, it is
possible that corticosteroids might counteract the aforementioned host
immune response that kills/degrades the larvae.
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Considerations for treatment of a horse
with parasite-induced colic
It should be emphasised that the considerations presented above strictly
apply to situations in which an asymptomatic horse tests positive for the
given parasite. Management of an active colic case of suspected parasitic
aetiology comes with a different set of considerations, largely dependent
on the clinical presentation. Typically, therapeutic interventions will focus
on pain management and normalising fluid and electrolyte balances, while
attempting to determine whether surgery is required. Possible anthelmintic
interventions, however, are not a priority in the emergency situation.
Some cases of small intestinal ascarid impaction can be approached with
medical treatment if the case does not have gastric reflux, and is generally
manageable. In such situations, anthelmintic treatment, perhaps with a
benzimidazole, could be considered as a crucial component of the
treatment plan, along with appropriate pain medication, spasmolytics, fluid
therapy and regular evaluation for gastric reflux. Surgical intervention is
indicated in cases where medical treatment does not resolve the
impaction. Published evidence indicates that surgery involving enterotomy
carries a poor prognosis [5,6]. In contrast, a recent retrospective study
reported survival of >1 year in 60% of foals in which impaction was
managed by manual evacuation of worms into the caecum, rather than by
enterotomy [16]. To balance these data, the success will depend
significantly on the worm burden, the time frame before deciding the
intervention and the local surgical/hospital structure.
The situation is quite different for S. vulgaris-associated colic cases, as
these typically involve intestinal ischaemia and infarction, which leads to
peritonitis [4]. Here, the extent of intestinal tissue damage and the severity
of accompanying peritonitis largely determine the prognosis. Anthelmintic
intervention is unlikely to exert any positive effects in this context as
intestinal infarction may require exploratory laparotomy and resection of
the affected portion of the intestine. Anthelmintic therapy in the form of
ivermectin or moxidectin should be considered once the patient has been
treated successfully and stabilised.
Closing remarks
The considerations given here only pertain to treatment of individual
horses diagnosed with Parascaris spp. or S. vulgaris infection. Obviously,
control of these parasites at the herd level requires a different set of
considerations, in particular, integrated management plans involving
diagnostic procedures that target all potential helminth species present
and best practice grazing practices. These issues are not within the scope
of this editorial. However, interested readers are referred to the parasite
control guidelines recently published by the American Association of
Equine Practitioners [2]. Further, details on the current levels of
anthelmintic resistance found in equine parasites worldwide have been
summarised in recent publications [8,17,18].
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